Mistakes and Myths: The Allies, Germany, and the Versailles Treaty, 1918–1921*
For nearly forty years, historians of twentieth-century diplomacy have argued that the Versailles treaty was more reasonable than its reputation suggests and that it did not of itself cause the Depression, the rise of Hitler, or World War II. Their efforts have had little effect, despite Margaret MacMillan’s best-selling Paris 1919. The distorted view of The Economic Consequences of the Peace and J. M. Keynes’s other works still dominates both the Anglo-American historical profession and the English-speaking educated public, though Zara Steiner pointed out in The Lights That Failed that the Versailles treaty was the mildest of the 1919–20 settlements. Despite scholarly opinion, condemnation of the Versailles treaty continues without cease. The latest addition to an immense literature, The Versailles Treaty and Its Legacy, by Edward M. Bennett and the late Norman A. Graebner,
LOCAL PUBLIC DEBT MANAGEMENT: LESSONS FROM GREECE IN INCLUSIVE ECONOMIC PERSPECTIVE
This paper discusses the potential dangers of adversarial debt management in China between central and local authorities. It draws lessons from Germany’s recent mishandling of the Greek debt crisis to illustrate nuances and stresses the wisdom of cooperation and mutual support in restoring balance to local Chinese finance. Inclusive economic theory provides additional insight.
Botulinum toxin in the management of chronic migraine: clinical evidence and experience
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.